Prehliadač alebo jeho nastavenia nie sú podporované.

Praktik.ai používa moderné webové technológie kvôli bezpečnosti, rýchlosti a spoľahlivému prihlasovaniu. Tento prehliadač ich nepodporuje alebo blokuje JavaScript, preto sa aplikácia nemusí správne načítať.

Aktualizujte prosím Chrome, Edge, Firefox alebo Safari na najnovšiu verziu a stránku potom obnovte.

Ak používate Windows 7, Windows 8 alebo Windows 8.1, Chrome a Edge už nemusia ponúkať novú verziu. V takom prípade použite novšie zariadenie alebo kontaktujte podporu Praktik.ai.

Prohlížeč nebo jeho nastavení nejsou podporované.

Praktik.ai používá moderní webové technologie kvůli bezpečnosti, rychlosti a spolehlivému přihlašování. Tento prohlížeč je nepodporuje nebo blokuje JavaScript, proto se aplikace nemusí správně načíst.

Aktualizujte prosím Chrome, Edge, Firefox nebo Safari na nejnovější verzi a stránku potom obnovte.

Pokud používáte Windows 7, Windows 8 nebo Windows 8.1, Chrome a Edge už nemusí nabízet novou verzi. V takovém případě použijte novější zařízení nebo kontaktujte podporu Praktik.ai.

Your browser or its settings are not supported.

Praktik.ai uses modern web technologies for security, speed, and reliable sign-in. This browser does not support them, or JavaScript is blocked, so the app may not load correctly.

Please update Chrome, Edge, Firefox, or Safari to the latest version and then reload this page.

If you use Windows 7, Windows 8, or Windows 8.1, Chrome and Edge may no longer offer a newer version. In that case, use a newer device or contact Praktik.ai support.

Effective REGULATION (EC) No 1902/2006 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 20 December 2006 amending Regulation 1901/2006 on medicinal products for paediatric use (Text with EEA relevance)

Vyhláška č. 1902/2006

Text language

Important dates

Declared: 20. decembra 2006
Approved: 20. decembra 2006
Effective from: 26. januára 2007

Documents and links

REGULATION (EC) No 1902/2006 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

of 20 December 2006

amending Regulation 1901/2006 on medicinal products for paediatric use

(Text with EEA relevance)

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty establishing the European Community, in particular Article 95 thereof,

Having regard to the proposal from the Commission,

Having regard to the opinion of the European Economic and Social Committee,

After consulting the Committee of the Regions,

Acting in accordance with the procedure laid down in Article 251 of the Treaty (1),

Whereas:

(1)

The measures necessary for the implementation of Regulation (EC) No 1901/2006 (2) should be adopted in accordance with Council Decision 1999/468/EC of 28 June 1999 laying down the procedures for the exercise of implementing powers conferred on the Commission (3).

(2)

In particular, the Commission should be empowered to define further the grounds for granting a deferral for the initiation or completion of some or all of the measures in the paediatric investigation plan and to specify the maximum amounts as well as the conditions and methods for collection of the financial penalties for infringement of the provisions of Regulation (EC) No 1901/2006 or the implementing measures adopted pursuant to it. Since these measures are of general scope and are designed to supplement Regulation (EC) No 1901/2006 by the addition of new non-essential elements, these measures should be adopted in accordance with the regulatory procedure with scrutiny provided for in Article 5a of Decision 1999/468/EC.

(3)

It is necessary to amend Regulation (EC) No 1901/2006 accordingly,

HAVE ADOPTED THIS REGULATION:

Article 1

Regulation (EC) No 1901/2006 is hereby amended as follows:

1)

in Article 20, paragraph 2 shall be replaced by the following:

‘2.   On the basis of the experience acquired as a result of the operation of this Article, the Commission may adopt provisions, in accordance with the regulatory procedure with scrutiny referred to in Article 51(2), amending or supplementing non-essential elements of this Regulation to define further the grounds for granting a deferral.’;

2)

in Article 49, paragraph 3 shall be replaced by the following:

‘3.   At the Agency's request, the Commission may impose financial penalties for infringement of the provisions of this Regulation or the implementing measures adopted pursuant to it in relation to medicinal products authorised through the procedure laid down in Regulation (EC) No 726/2004. Measures amending or supplementing non-essential elements of this Regulation concerning the maximum amounts as well as the conditions and methods for collection of those penalties shall be adopted in accordance with the regulatory procedure with scrutiny referred to in Article 51(2).’;

3)

in Article 51, paragraph 2 shall be replaced by the following:

‘2.   Where reference is made to this paragraph, Article 5a(1) to (4) and Article 7 of Decision 1999/468/EC shall apply, having regard to the provisions of Article 8 thereof.’.

Article 2

This Regulation shall enter into force on the thirtieth day following that of its publication in the Official Journal of the European Union.

This Regulation is binding in its entirety and directly applicable in all Member States.

Done at Brussels, 20 December 2006

For the European Parliament

The President

J. BORRELL FONTELLES

For the Council

The President

J. KORKEAOJA

Poznámky

(1)  Opinion of the European Parliament of 14 December 2006 (not yet published in the Official Journal) and Council Decision of 19 December 2006.

(2)  See page 1 of this Official Journal

(3)   OJ L 184, 17.7.1999, p. 23. Decision as amended by Decision 2006/512/EC (OJ L 200, 22.7.2006, p. 11).